American Shared Hospital Services (AMS) reported a third-quarter loss of $0.09 per share on revenue of $7.62 million, well short of the $0.01 profit consensus expected. That works out to a -1000.0% earnings surprise. Revenue missed the $8.53 million consensus by 10.6% while growing just 6.3% year over year. The loss widened sharply from essentially breakeven a year ago, when the net loss attributable to AMS was only $17,000. The central tension is that the operating business lost momentum just as the balance sheet was improving. Liquidity strengthened meaningfully, but the growth story that carried the second quarter slowed abruptly, and revenue declined sequentially from $8.4 million in Q2.

The quality of the quarter deserves scrutiny. Direct Patient Services revenue rose 13.6% to $4.6 million, a sharp slowdown from roughly 40% growth in Q2. Revenue at the Rhode Island and Puebla facilities increased 13.5% to $3.3 million even though radiation therapy procedures fell to 7,143 from 7,355. Pricing or mix, not volume, is doing the work there. Medical Equipment Leasing slipped 3.1% to $3.0 million. Proton beam revenue fell to $2.0 million as treatment fractions dropped to 960 from 1,150, a reversal after Q2's 22% PBRT revenue gain. Management called the PBRT fluctuation normal cyclicality.

The cost side was worse. Costs of revenue rose to $6.1 million from $5.6 million, pushing gross margin down to 19.9% from 22.1%. Selling and administrative expense climbed to $1.8 million from $1.5 million on legal, banking and consulting fees tied to the Fifth Third credit amendment. Interest expense also rose. Adjusted EBITDA fell to $1.4 million from $1.9 million, so the deterioration was not merely a GAAP artifact.

The conference call reinforced the sense of a quarter that lost its footing. The tone was notably more subdued than Q2's "firing on all cylinders" framing, and the executive chairman described Rhode Island as "two steps forward, one step back." Management raised the allowance for credit losses on Rhode Island receivables again, following a $909,000 charge in Q2. That is an uncomfortable pattern for the segment driving most of the company's growth.

Gamma Knife was a genuine bright spot:

• The Peru Esprit upgrade drove international procedures up 8.9% in the quarter.
• Domestic Gamma Knife volume rose 13.1%.
• Management cited roughly 11% overall Gamma Knife procedure growth on the call.

The development pipeline, however, keeps slipping. The Hospital San Javier joint venture in Guadalajara now targets first treatments in mid-2027, after earlier calls pointed to 2026 and then Q2 2026. Expansion beyond current projects is on hold until the lender relationship is resolved. No formal guidance was provided.

The offset is liquidity, and it is real:

• Cash, equivalents and restricted cash reached about $9.5 million, up from $6.8 million at mid-year and $3.7 million at year-end 2025.
• Nine-month operating cash flow totaled $5.8 million, versus $4.4 million through the first half.
• The current portion of long-term debt fell to about $15.7 million in the release ($15.6 million on the call) from $17.3 million.
• The working capital deficit narrowed to $4.6 million from $5.7 million.

Forbearance with Fifth Third runs through June 30, 2027. An entity controlled by the executive chairman supplied $2.0 million of subordinated financing. Management says it is exploring longer-term capital structure alternatives, and the Third Amendment retains a sale-process covenant. Bears have legitimate ammunition here: cash still covers well under the debt now due within a year, the company operates under forbearance, and leadership includes an interim CEO. The improving cash position makes a refinancing path more plausible, but it does not resolve the issue.

The market treated the stock harshly heading into the report. Shares opened at $1.58 after the August release and touched an inter-earnings high of $1.63 that day. They then slid to a 52-week low of $1.14 on November 6, less than a week before this report, roughly 28% below the post-report open. The Earnings Whispers price and AVWAP trend readings are negative, with momentum neutral, consistent with persistent selling pressure rather than anticipation of a rebound. A sizable miss and slowing growth give investors little reason to reassess that posture quickly.

The bottom line is that AMS delivered a weak quarter on nearly every operating measure: a deep EPS and revenue miss, decelerating growth, compressed margins, rising credit-loss concerns and another delay at Guadalajara. Steadily rising cash and positive operating cash flow give the company time to work through its lender situation. Until Rhode Island collections stabilize, volumes recover and the capital structure is resolved, the balance-sheet progress looks more like a defensive buffer than the foundation of a renewed growth story.